| [1] |
LIN Yicong, WANG Yue, XUE Qianqian, ZHENG Qiang, JIN Yan, HUANG Ziling, LI Yuan.
Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications
[J]. China Oncology, 2024, 34(4): 368-379.
|
| [2] |
WANG Shanshan, YE Dingwei, YANG Li, CHENG Fan, YANG Tiejun, ZHANG Xiaoping, YU Zhixian, ZHANG Qingyun, YANG Yong.
Correlation of HER2 expression and clinicopathological characteristics in patients with urothelial carcinoma in China
[J]. China Oncology, 2024, 34(11): 1011-1019.
|
| [3] |
ZHAO Junxiu, ZHU Yi, SONG Xiaoyu, ZHE Chao, XIAO Yuhan, LIU Yunduo, LI Linhai, XIAO Bin.
Circ-0007766 acts as a miR-1972 sponge to promote breast cancer cell migration and invasion via upregulation of HER2
[J]. China Oncology, 2024, 34(10): 915-930.
|
| [4] |
Cancer Rehabilitation and Palliative Professional Committee of Shanghai Anti-Cancer Association , Cancer Drug Clinical Research Committee of Shanghai Anti-Cancer Association , Cancer Prevention and Clinical Research Committee of Chinese Aging Well Association .
Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition)
[J]. China Oncology, 2024, 34(1): 104-134.
|
| [5] |
ZHANG Lingling, WANG Xiangyi, WEI Xing, LIN Li, TANG Chuanhao, LIANG Jun.
A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis
[J]. China Oncology, 2023, 33(8): 776-781.
|
| [6] |
KANG Yinnan, CHEN Shun, XIE Youcheng, ZHENG Ying, HE Yujing, LI Chuyi, YU Xiaohui.
Application and research progress of antibody drug conjugates in HER2 positive advanced gastric cancer
[J]. China Oncology, 2023, 33(8): 790-800.
|
| [7] |
WANG Ruoxi, JI Peng, GONG Yue, CHEN Sheng.
Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study
[J]. China Oncology, 2023, 33(7): 686-692.
|
| [8] |
YANG Wenxiao, GUO Linwei, LING Hong, HU Xin.
Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy
[J]. China Oncology, 2023, 33(5): 484-498.
|
| [9] |
LIU Yang, HU Yiyang, LIU Yueping, NIU Shuyao, DING Pingan, TIAN Yuan, GUO Honghai, YANG Peigang, ZHANG Ze, ZHENG Tao, TAN Bibo, FAN Liqiao, LI Yong, ZHAO Qun.
The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy
[J]. China Oncology, 2023, 33(4): 377-387.
|
| [10] |
SU Chunxia, ZHOU Caicun.
Important clinical research progress in lung cancer in 2022
[J]. China Oncology, 2023, 33(3): 218-227.
|
| [11] |
SHAO Zhibo, YANG Benlong, WU Jiong.
Progress of important clinical trials of breast cancer in China in 2022
[J]. China Oncology, 2023, 33(2): 103-109.
|
| [12] |
WANG Xueer, WANG Yongsheng.
The research advances and the clinical value of antibody-drug conjugate from molecular subtyping of breast cancer in the era of "precision medicine"
[J]. China Oncology, 2023, 33(12): 1073-1082.
|
| [13] |
Energizing Specialty Construction-Multidisciplinary Expert Committee for Creating Healthy China, The Society of Breast Cancer China Anti-Cancer Association.
Standardization of multi disciplinary team treatment for breast cancer (2023 edition)
[J]. China Oncology, 2023, 33(12): 1188-1203.
|
| [14] |
HE Liyuan, WANG Yudong.
Research progress of ALK kinase domain drug resistance mutation and its future countermeasures
[J]. China Oncology, 2022, 32(8): 736-746.
|
| [15] |
HONG Yaping, HUANG Yunjian, HUANG Zhangzhou, CHEN Shengjia, ZHONG Qiaofeng, ZENG Hongfu, ZHUANG Wu.
Efficacy and prognostic predictors of first-generation EGFR TKI-targeted therapy in patients with EGFR-mutated advanced non-small cell lung cancer
[J]. China Oncology, 2022, 32(7): 624-634.
|
